

# Estrogen-Only HT Tied to Higher Asthma Risk

BY JENNIE SMITH

**E**strogen-only hormone therapy has been shown to increase the risk of developing asthma after menopause by 54% among postmenopausal women compared with those who have never been treated with HT, according to data from a health survey of French women.

Researchers at the National Institute of Public Health, Cuernavaca, Mexico, and INSERM and the Université Paris-Sud, France, used data from the E3N cohort, a health survey of nearly 100,000 French women who were born between 1925 and 1950.

The women, mostly teachers, responded to biannual questionnaires between 1990 and 2002 (Thorax 2010 Feb. 8 [doi:10.1136/thx.2009.116079]).

Of the 57,664 women who were free of asthma at menopause, just under two-thirds used some sort of HT, and 569 were later diagnosed with asthma.

The study, which was led by Dr. Isabelle Romieu of the Mexican institute, found that “the increased risk of asthma onset among women using [HT] was

**‘Fifty-eight percent of women reporting the use of estrogen alone at the time of asthma onset or as last treatment before asthma onset had previously used another [HT].’**

present only in users of estrogen alone [hazard ratio 1.54]. The effect was observed only in recent users including current users and women for whom time since last use was less than 1.5 years.”

Moreover, the authors wrote, “Fifty-eight percent of women reporting the use of estrogen alone at the time of asthma onset or as last treatment before asthma onset had previously used another [HT]. This supports our finding that the increased risk of asthma onset is linked to estrogen use.”

The authors found that the risk of developing asthma increased to 80% and 86% (hazard ratios of 1.80 and 1.86), respectively, among postmenopausal women who were treated with estrogen-only HT who never smoked or had a history of allergies before menopause, compared with women who were untreated.

The authors cautioned, however, that the allergy histories were self-reported and that potential misclassifications of allergic disease could have occurred.

The apparently lower susceptibility of HT-treated women who smoke or have smoked to postmenopausal asthma had been noted in earlier studies, Dr. Romieu and her couthors wrote.

“This might be due to the antioestrogenic effect of smoking or to the difficulty of isolating the additional effect of [HT] among smokers,” they noted.

Female hormones have long been suspected of playing a role in the development of asthma, and the connection between HT and postmenopausal asthma had been investigated in a large-scale U.S. study published several years ago (Arch. Int. Med. 2004;164:379-86).

That study determined that recent HT treatment was linked to an increased risk of postmenopausal patients developing asthma. But the study found

the risk to be similar whether patients were treated with estrogen only or with a combination of estrogen and progestin.

As a possible explanation for the disparity, Dr. Romieu and her colleagues offered the fact that French and American physicians generally use different ratios of estrogen and progestin, as well as different types of progestin, in HT treatment regimens.

Also in contrast to the earlier U.S. study, Dr. Romieu’s team of investigators did not observe interactions between body mass index and risk of asthma among HT and non-HT patients following menopause, but they indicated that this may have been because the French cohort presented leaner body mass as a whole.

The study investigators reported no financial conflicts of interest. ■



Model is for illustrative purposes only.

NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

#### Important safety information

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin. Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy.

To access complimentary e-learning programs, visit [novomedlink.com/NovoLog](http://novomedlink.com/NovoLog).

NovoLog® helps put glycemic control within reach by managing mealtime glucose. Not only that, NovoLog® is proven to help a wide variety of patients get to the next level of treatment:

- Adults with type 1 diabetes
- Adults with type 2 diabetes
- Children and adolescents with type 1 diabetes
- Pump users (adults and children/adolescents)
- Geriatric patients
- Pregnant women (Category B)



**NOVOLOG®**  
insulin aspart (rDNA origin) injection



Please see brief summary of Prescribing Information on a adjacent page.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.  
©2008 Novo Nordisk Inc. 136404

October 2008